Advaxis, Inc.

OS Therapies Incorporated launched the 14th biopharmaceutical company initial public offering in the US in 2024 on 31 July, selling 1.6 million shares at $4 each to gross $6.4m in the smallest IPO so

Troubled Advaxis, Inc. may be getting a second lease on life by merging with cash-poor Ayala Pharmaceuticals, Inc. , which has a late-stage candidate for desmoid tumors, a condition with no approve

BioNTech has presented promising early results from the neoantigen targeting cancer immunotherapy it is developing with Roche , as it seeks to advance its multi-pronged oncology ambitions. Autogene

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca Offloads Phase III-Ready Su